Acute Stroke Management in Türkiye: Intravenous Tissue Plasminogen Activator and Thrombectomy NöroTek: Türkiye Neurology Single Day Study.

Objective: To reveal the profile and practice in patients with acute stroke who received intravenous tissue plasminogen activator (IV tPA) and/or neurointerventional therapy in Türkiye. Materials and Methods: On World Stroke Awareness Day, May 10, 2018, 1,790 patients hospitalized in 87 neurology units spread over 30 health regions were evaluated retrospectively and prospectively. Results: Intravenous tPA was administered to 12% of 859 cases of acute ischemic stroke in 45 units participating in the study. In the same period, 8.3% of the cases received neurointerventional treatment. The rate of good prognosis [modified Rankin score (mRS) 0--2] at discharge was 46% in 83 patients who received only IV tPA [age: 67 ± 12 years; National Institutes of Health Stroke Scale (NIHSS): 12 ± 6; hospital stay, 24 ± 29 days]; 35% in 51 patients who underwent thrombectomy (MT) alone (age: 64 ± 13 years; NIHSS: 14.1 ± 6.5; length of hospital stay, 33 ± 31 days), 19% in those who received combined treatment (age: 66 ± 14 years; NIHSS: 15.6 ± 5.4; length of hospital stay, 26 ± 35 days), and 56% of 695 patients who did not receive treatment for revascularization (age: 70 ± 13 years; NIHSS: 7.6 ± 7.2; length of hospital stay, 21 ± 28 days). The symptom-to-door time was 87 ± 53 minutes in the IV treatment group and 200 ± 26 minutes in the neurointerventional group. The average door-to-needle time was 66 ± 49 minutes in the IV tPA group. In the neurothrombectomy group, the door-to-groin time was 103 ± 90 minutes, and the TICI 2b-3 rate was 70.3%. In 103 patients who received IV tPA, the discharge mRS 0--2 was 41%, while the rate of mRS 0--1 was 28%. In 71 patients who underwent neurothrombectomy, the mRS 0--2 was 31% and mRS 0--1 was 18%. The door-to-groin time was approximately 30 minutes longer if IV tPA was received (125 ± 107 and 95 ± 83 minutes, respectively). Symptomatic bleeding rates were 4.8% in IV recipients, 17.6% among those who received only MT, and 15% in combined therapy. Globally, the hemorrhage rate was 6.8% in patients receiving IV tPA and 16.9% in MT. Conclusion: IV thrombolytic and neurointerventional treatment applications in acute ischemic stroke in Türkiye can provide the anticipated results. Heterogeneity has begun to be reduced in our country with the dissemination of the system indicated by the "Directive on Health Services to be Provided to Patients with Acute Stroke." [ABSTRACT FROM AUTHOR]

Amaç: Türkiye'de intravenöz doku plazminojen aktivatörü (IV tPA) ve/veya nöro-girişimsel tedavi uygulanan akut inme hastalarının profili ve uygulamaya dair pratiklerin ortaya konulması. Gereç ve Yöntem: 10 Mayıs 2018 Dünya İnme Farkındalık Günü'nde 30 sağlık bölgesine yayılmış olan 87 nöroloji biriminde yatmakta olan 1.790 hasta retrospektif ve prospektif olarak değerlendirilmiştir. Bulgular: Çalışmaya katılan 45 birimde 859 akut iskemik inme olgusundan %12'sine IV tPA uygulanmıştır. Aynı dönemde %8,3 olgu nörogirişimsel tedavi almıştır. Taburculuk esnasında iyi prognoz [modifiye Rankin skoru (mRS) 0--2] oranı sadece IV tPA uygulanan 83 olguda [yaş: 67 ± 12 yıl; Ulusal Sağlık İnme Ölçeği (NIHSS): 12 ± 6, hastanede yatış süresi 24 ± 29 gün] %46; sadece trombektomi (MT) uygulanan 51 olguda (yaş: 64 ± 13 yıl; NIHSS: 14,1 ± 6,5; hastanede yatış süresi 33 ± 31 gün) %35, kombine tedavi alanlarda (yaş: 66 ± 14 yıl, NIHSS: 15,6 ± 5,4, yatış süresi 26 ± 35 gün) %19 ve revaskülarizasyona yönelik tedavi uygulanmayan 695 olguda (yaş: 70 ± 13 yıl, NIHSS 7,6 ± 7,2; ortalama yatış süresi: 21 ± 28 gün) %56'dır. Semptom kapı zamanı IV tedavi alanlarda 87 ± 53 dakika iken nörogirişimsel grupta 200 ± 26 dakikadır. IV tPA grubunda ortalama kapı iğne zamanı 66 ± 49 dakikadır. Nörotrombektomi grubunda kapı-kasık zamanı 103 ± 90 dakika ve TICI 2b-3 oranı %70,3'dür. IV tPA uygulaması yapılan 103 olguda taburculuk mRS 0--2 %41 iken mRS 0--1 oranı %28 olarak belirlenmiştir. Toplam nörotrombektomi uygulanan 71 olguda mRS 0-2 %31 ve mRS 0-1 %18 olarak kaydedilmiştir. Kapı-kasık girişi zaman IV tPA almış ise yaklaşık yarım saat daha uzundur (sırasıyla; 125 ± 107 dakika ve 95 ± 83 dakika). Semptomatik kanama oranları ise sadece IV alanlarda %4,8; sadece MT yapılanlarda %17,6; kombine tedavide %15 olup IV alan hastalarda global olarak %6,8 ve MT'de %16,9'dur. Sonuç: Türkiye'de akut iskemik inmede IV trombolitik ve nörogirişimsel tedavi uygulamaları beklenen sonuçları sağlayabilmektedir. Ülkemizde "Akut İnmeli Hastalara Verilecek Sağlık Hizmetleri Hakkında Yönerge"nin işaret ettiği sistemin yaygınlaştırılması ile heterojenite azaltılma yoluna girmiştir. [ABSTRACT FROM AUTHOR]

Copyright of Turkish Journal of Neurology / Turk Noroloji Dergisi is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)